Dual GLP-1/glucagon receptor agonism is one of the most closely watched mechanisms in metabolic peptide research, sitting conceptually between single-receptor GLP-1 agonists and the triple agonists covered in our next-gen weight loss peptides overview. Two compounds anchor this class in the current literature: survodutide (BI 456906), developed by Boehringer Ingelheim in partnership with Zealand Pharma, and mazdutide (IBI362, also referenced as LY3305677), developed by Innovent Biologics with Eli Lilly. This article compares their mechanisms, published trial data, and handling considerations, strictly for research and educational purposes.
What Is Survodutide?
Survodutide (BI 456906) is a long-acting peptide dual agonist of the glucagon receptor (GCGR) and the GLP-1 receptor (GLP-1R). It originated from a partnership between Zealand Pharma, which discovered the molecule, and Boehringer Ingelheim, which holds global development and commercialization rights. Survodutide is being investigated as a once-weekly subcutaneous research compound in two overlapping programs: obesity/overweight and metabolic dysfunction-associated steatohepatitis (MASH), the disease previously known as NASH. Dosage-guide references for survodutide are available at survodutide 5mg and survodutide 10mg.
What Is Mazdutide?
Mazdutide (IBI362, also designated LY3305677) is described in the literature as an oxyntomodulin analog — a synthetic peptide modeled on the naturally occurring gut hormone oxyntomodulin, which itself has weak dual activity at GLP-1 and glucagon receptors. Mazdutide was engineered to amplify and balance this dual activity. It is being co-developed by Innovent Biologics, which holds rights in Greater China, and Eli Lilly, which retains rights in other territories. Mazdutide has progressed through a multi-study Chinese Phase 3 program under the “GLORY” trial name for both weight management and type 2 diabetes. Reference material is available at mazdutide 5mg and mazdutide 10mg.
Mechanism of Action
Both peptides sit in the same pharmacological class — dual GLP-1R/GCGR agonists — but they are distinct molecules with different peptide backbones and receptor-activation ratios.
Shared mechanistic logic:
- GLP-1 receptor activation slows gastric emptying, promotes glucose-dependent insulin secretion, and acts on hypothalamic satiety centers to reduce food intake — the same pathway exploited by semaglutide and other single-agonist GLP-1 peptides.
- Glucagon receptor activation is the differentiating piece. Rather than raising blood glucose the way endogenous glucagon does during fasting, at the doses studied the GCGR component is investigated for its potential to increase energy expenditure and promote hepatic lipid oxidation — a rationale for why both compounds are studied not just for weight but for liver-fat-related endpoints.
Where they may differ: Published pharmacology suggests survodutide and mazdutide are not identically balanced between the two receptors, and each has its own titration/dosing scheme in clinical development. Head-to-head receptor-binding-ratio data comparing the two directly in the same assay system is limited in the public literature, so any claim of one being “more GCGR-biased” than the other should be treated as provisional pending further peer-reviewed comparative pharmacology.
Research Background & Key Findings
Survodutide — obesity (Phase 2). le Roux et al. (2024), published in The Lancet Diabetes & Endocrinology, reported a 46-week, randomized, double-blind, placebo-controlled, dose-finding Phase 2 trial in adults with overweight or obesity without diabetes (doses of 0.6, 2.4, 3.6, and 4.8 mg weekly). Survodutide dose-dependently reduced body weight, with reductions of up to roughly 12% versus placebo at the highest dose studied, and the majority of participants on the 4.8 mg dose achieved at least 15% body-weight loss. The weight-loss curve had not clearly plateaued by week 46, suggesting further loss with longer treatment durations remains a research question.
Survodutide — MASH (Phase 2). Sanyal et al. (2024), published in the New England Journal of Medicine (NEJMoa2401755), reported a Phase 2 trial in participants with biopsy-confirmed MASH and fibrosis stages F1–F3. Up to roughly 83% of participants on survodutide achieved histologic improvement in MASH without worsening of fibrosis, compared with about 18% on placebo — a statistically significant difference that also extended to secondary fibrosis endpoints. This trial supported a subsequent FDA Breakthrough Therapy designation for survodutide in non-cirrhotic MASH and the initiation of Phase 3 trials.
Survodutide — later-stage obesity data. More recent Phase 3 disclosures (Zealand Pharma/Boehringer Ingelheim, 2026) from the SYNCHRONIZE program have reported body-composition findings, including targeted visceral and liver fat reductions alongside relative preservation of lean mass in a pre-specified analysis — consistent with the mechanistic rationale for GCGR co-agonism, though full peer-reviewed Phase 3 efficacy results should be consulted once published.
Mazdutide — dose-ranging (Phase 2). Ji et al., in a randomized controlled Phase 2 trial in Chinese adults with overweight or obesity (published in Nature Communications), evaluated a range of mazdutide doses and reported dose-dependent weight reduction with a tolerability profile broadly similar to other incretin-based peptides.
Mazdutide — Phase 3 (GLORY program). Innovent Biologics reported that the Phase 3 GLORY-1 trial met its primary and key secondary endpoints in Chinese adults with overweight or obesity: at week 48, the mazdutide 6 mg group showed a treatment difference versus placebo of roughly −14.3% in body weight. A second Phase 3 trial, GLORY-2, evaluating a 9 mg dose over 60 weeks, reported that 44.0% of participants receiving mazdutide 9 mg achieved ≥20% weight loss, versus 2.6% on placebo. Innovent has also progressed regulatory submissions for mazdutide in chronic weight management with China’s NMPA.
Figures come from separate trial programs and are illustrative, not head-to-head.
Because survodutide and mazdutide have so far been studied largely in separate trial programs, populations, and geographies (global multi-region programs for survodutide versus predominantly Chinese cohorts for mazdutide to date), cross-trial percentage comparisons should be read as illustrative rather than as head-to-head evidence — differences in trial design, baseline BMI, and duration all affect outcome magnitude.
Comparison Table
| Survodutide (BI 456906) | Mazdutide (IBI362 / LY3305677) | |
|---|---|---|
| Developer | Boehringer Ingelheim (global rights), discovered by Zealand Pharma | Innovent Biologics (Greater China), Eli Lilly (other territories) |
| Molecule class | Dual GLP-1 receptor / glucagon receptor agonist peptide | Oxyntomodulin analog; dual GLP-1 receptor / glucagon receptor agonist peptide |
| Primary research indications | Obesity/overweight; MASH (metabolic dysfunction-associated steatohepatitis) | Obesity/overweight; type 2 diabetes |
| Key trials cited | le Roux et al. 2024 (Lancet Diabetes & Endocrinology, Phase 2 obesity); Sanyal et al. 2024 (NEJM, Phase 2 MASH); SYNCHRONIZE Phase 3 program | Ji et al. (Nature Communications, Phase 2); GLORY-1 and GLORY-2 (Phase 3) |
| Reported endpoints | Dose-dependent body-weight reduction (~12%+ vs placebo at 4.8 mg, Phase 2); ~83% MASH improvement without fibrosis worsening at highest dose vs ~18% placebo; visceral/liver fat reduction in later-stage data | Dose-dependent body-weight reduction; ~14.3% placebo-adjusted weight change at 6 mg (48 weeks, GLORY-1); 44.0% of 9 mg group reaching ≥20% weight loss (GLORY-2) |
| Regulatory status (as of mid-2026) | Phase 3 (obesity and MASH programs); FDA Breakthrough Therapy designation (non-cirrhotic MASH) | Phase 3 completed/reported in China; NMPA submission for chronic weight management |
| Dosing frequency studied | Once weekly, subcutaneous | Once weekly, subcutaneous |
Forms, Reconstitution & Handling
In research settings, both peptides are typically supplied as lyophilized (freeze-dried) powder in multi-dose vials, requiring reconstitution with bacteriostatic water (BAC water) before use in a study protocol. Vial strengths commonly referenced for survodutide and mazdutide research materials include 5 mg and 10 mg formats — see the survodutide 5mg, survodutide 10mg, mazdutide 5mg, and mazdutide 10mg reference pages for concentration and mixing-ratio detail relevant to laboratory record-keeping.
General handling notes applicable to peptide research work:
- Reconstitute gently — direct a slow stream of bacteriostatic water down the inside wall of the vial rather than injecting directly onto the lyophilized cake, and swirl (do not shake) to avoid denaturing the peptide.
- Use sterile technique throughout: alcohol-swab stoppers, single-use needles, and appropriately calibrated syringes for the volumes involved.
- Label vials clearly with compound, concentration, and reconstitution date to maintain an accurate laboratory record.
Research Considerations
Researchers designing or reviewing protocols involving dual GLP-1/glucagon agonists commonly note the following general considerations, presented here for educational context and not as instructions for use:
- Titration approach. Published trials for both compounds used gradual dose escalation over multiple weeks, consistent with the broader incretin-peptide class, to characterize tolerability at each step before advancing.
- Tolerability profile. Across both molecules, the most frequently reported adverse events in published trials were gastrointestinal (nausea, vomiting, diarrhea), a pattern shared with single-agonist GLP-1 compounds and attributed largely to the GLP-1 receptor component.
- Population and trial-design differences. As noted above, survodutide’s public dataset spans global, multi-region trials, while mazdutide’s Phase 3 program to date has focused on Chinese populations — a factor to weigh when extrapolating findings across ethnic or regional cohorts.
- Comparative studies remain limited. No large, direct head-to-head trial comparing survodutide and mazdutide in the same population has been published as of this writing; comparisons in this article draw on separate trial programs.
Storage & Stability
General cold-chain principles reported for peptide research compounds in this class:
| Form | Typical Storage | Notes |
|---|---|---|
| Lyophilized (unreconstituted) | −20°C, extended stability (often cited as 2+ years) | Protect from light and repeated freeze-thaw cycles |
| Reconstituted | 2–8°C (refrigerated) | Commonly cited stability window of 4–6 weeks; use a labeled, dated vial |
Always confirm specific storage parameters against the certificate of analysis (COA) or manufacturer documentation for the specific research lot in use, since stability data can vary by formulation and excipients.
Safety, Legality & Research Disclaimers
Survodutide and mazdutide are investigational compounds under active clinical development. Neither is approved for general human medical use in the European Union or the United States as of this writing; mazdutide has advanced further in regulatory review in China specifically. Both compounds discussed here are intended strictly for laboratory and research purposes — not for human or animal consumption, self-administration, or diagnostic/therapeutic use outside of a properly authorized clinical trial. Researchers are responsible for complying with all applicable EU, national, and institutional regulations regarding the acquisition, storage, and use of investigational peptides, including biosafety and chemical-handling rules. Nothing in this article constitutes medical advice, and no dosing information presented anywhere on PeptiMap should be interpreted as a recommendation for human or animal use.
FAQ
Are survodutide and mazdutide the same drug? No. They are distinct peptide molecules developed by different companies (Boehringer Ingelheim/Zealand Pharma versus Innovent Biologics/Eli Lilly), though they share the same broad pharmacological class — dual GLP-1 receptor/glucagon receptor agonism.
What is the main difference in how they’ve been studied? Survodutide’s published trial program spans both obesity and MASH (liver disease) indications with global, multi-region participant pools, while mazdutide’s Phase 3 program to date has centered on weight management and type 2 diabetes in Chinese cohorts.
Is one more effective than the other for weight loss? Direct, head-to-head comparative trial data is not currently available in the public literature. Reported placebo-adjusted weight-loss figures from separate trials are in a broadly similar range, but differences in trial design, dose, duration, and population make a definitive efficacy ranking premature.
Why is the glucagon receptor component included at all? The rationale under investigation is that GCGR co-activation may add energy-expenditure and hepatic-lipid-oxidation effects on top of the well-established GLP-1 appetite/glycemic pathway, which is why both peptides are being studied for liver-fat-related endpoints in addition to body weight.
Are these peptides approved medicines? No, not in the EU or US as of this writing. Both remain investigational; mazdutide has progressed furthest in China’s regulatory process. Any research use should track official regulatory status and published, peer-reviewed data rather than preliminary press disclosures.
Where can I find dosing-guide reference material for these peptides? See the survodutide 5mg, survodutide 10mg, mazdutide 5mg, and mazdutide 10mg pages, and our broader next-gen weight loss peptides overview for context on how these compounds fit into the wider incretin-peptide pipeline.
References
- le Roux CW, et al. “Glucagon and GLP-1 receptor dual agonist survodutide for obesity: a randomised, double-blind, placebo-controlled, dose-finding phase 2 trial.” The Lancet Diabetes & Endocrinology, 2024.
- Sanyal AJ, et al. “A Phase 2 Randomized Trial of Survodutide in MASH and Fibrosis.” New England Journal of Medicine, 2024 (NEJMoa2401755).
- Ji L, et al. “A phase 2 randomised controlled trial of mazdutide in Chinese overweight adults or adults with obesity.” Nature Communications, 2024.
- Innovent Biologics. “Innovent Presents the Results of the First Phase 3 Study of Mazdutide for Weight Management at the ADA’s 84th Scientific Sessions” (GLORY-1 trial), 2024.
- Zealand Pharma / Boehringer Ingelheim. “Survodutide Phase III trial in people living with obesity showed targeted visceral and liver fat reduction, while minimizing lean mass loss in pre-specified analysis.” GlobeNewswire, 2026.
This article is for educational and research purposes only. Survodutide and mazdutide are investigational research compounds, not approved medicines for general human use in the EU. Nothing here constitutes medical advice.